Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-paclitaxel-reffactory breast cancer patients

Giuseppe Frasci, Giuseppe D'Aiuto, Renato Thomas, Pasquale Comella, Maurizio Di Bonito, Liliana Lapenta, Massimiliano D'Aiuto, Gerardo Botti, Paolo Vallone, Vincenzo De Rosa, Roberta D'Aniello, Renato Giordano, Giuseppe Comella

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the feasibility and activity of combination treatment with docetaxel (DTX) and irinotecan (CPT-11), given together every other week, combined with filgrastim support, in anthracycline- and paclitaxel-pretreated breast cancer (BC) patients. Patients and Methods: Advanced BC patients pretreated with anthracycline- and paclitaxel-based chemotherapy were eligible. DTX (80 mg/m2) and CPT-11 (100 mg/m2) were given biweekly with filgrastim support (300 μg/day on days 4-7). Results: Fifty patients (48 with metastatic and 2 with locally advanced cancer) were enrolled, with a total of 318 cycles being delivered. Thirty-one patients had visceral localizations. All patients had received epirubicin plus paclitaxel, with or without cisplatin, as front-line treatment for advanced disease. Overall, fatigue and diarrhea were the main chemotherapy-related toxicities in this study, being severe in 10 (20%) and 4 (8%) patients. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 18 (36%) and 6 (12%) patients, respectively. Red blood cell transfusions were required in 4 patients. A total of 32 objective responses were registered (overall response rate, ORR = 64%, 95% confidence interval = 49-77%), including 8 complete responses (16%). An additional 8 patients showed stable disease. After a median follow-up of 18 (range 4-29) months, 30 patients were still alive, and 19 were progression free; median progression-free and overall survivals were 10 and 23 months, respectively. Conclusions: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients. The very promising ORR and survival outcome observed in this subset of patients with a poor prognosis suggest that this regimen might play a major role in the management of this disease.

Original languageEnglish
Pages (from-to)391-397
Number of pages7
JournalOncology
Volume68
Issue number4-6
DOIs
Publication statusPublished - Aug 2005

Fingerprint

irinotecan
docetaxel
Paclitaxel
Breast Neoplasms
Therapeutics
Anthracyclines
Filgrastim

Keywords

  • Biweekly administration
  • Breast cancer
  • Docetaxel
  • Irinotecan

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-paclitaxel-reffactory breast cancer patients. / Frasci, Giuseppe; D'Aiuto, Giuseppe; Thomas, Renato; Comella, Pasquale; Di Bonito, Maurizio; Lapenta, Liliana; D'Aiuto, Massimiliano; Botti, Gerardo; Vallone, Paolo; De Rosa, Vincenzo; D'Aniello, Roberta; Giordano, Renato; Comella, Giuseppe.

In: Oncology, Vol. 68, No. 4-6, 08.2005, p. 391-397.

Research output: Contribution to journalArticle

Frasci, Giuseppe ; D'Aiuto, Giuseppe ; Thomas, Renato ; Comella, Pasquale ; Di Bonito, Maurizio ; Lapenta, Liliana ; D'Aiuto, Massimiliano ; Botti, Gerardo ; Vallone, Paolo ; De Rosa, Vincenzo ; D'Aniello, Roberta ; Giordano, Renato ; Comella, Giuseppe. / Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-paclitaxel-reffactory breast cancer patients. In: Oncology. 2005 ; Vol. 68, No. 4-6. pp. 391-397.
@article{99684055bec040a08d81573b7ab8d9dc,
title = "Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-paclitaxel-reffactory breast cancer patients",
abstract = "Purpose: To evaluate the feasibility and activity of combination treatment with docetaxel (DTX) and irinotecan (CPT-11), given together every other week, combined with filgrastim support, in anthracycline- and paclitaxel-pretreated breast cancer (BC) patients. Patients and Methods: Advanced BC patients pretreated with anthracycline- and paclitaxel-based chemotherapy were eligible. DTX (80 mg/m2) and CPT-11 (100 mg/m2) were given biweekly with filgrastim support (300 μg/day on days 4-7). Results: Fifty patients (48 with metastatic and 2 with locally advanced cancer) were enrolled, with a total of 318 cycles being delivered. Thirty-one patients had visceral localizations. All patients had received epirubicin plus paclitaxel, with or without cisplatin, as front-line treatment for advanced disease. Overall, fatigue and diarrhea were the main chemotherapy-related toxicities in this study, being severe in 10 (20{\%}) and 4 (8{\%}) patients. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 18 (36{\%}) and 6 (12{\%}) patients, respectively. Red blood cell transfusions were required in 4 patients. A total of 32 objective responses were registered (overall response rate, ORR = 64{\%}, 95{\%} confidence interval = 49-77{\%}), including 8 complete responses (16{\%}). An additional 8 patients showed stable disease. After a median follow-up of 18 (range 4-29) months, 30 patients were still alive, and 19 were progression free; median progression-free and overall survivals were 10 and 23 months, respectively. Conclusions: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients. The very promising ORR and survival outcome observed in this subset of patients with a poor prognosis suggest that this regimen might play a major role in the management of this disease.",
keywords = "Biweekly administration, Breast cancer, Docetaxel, Irinotecan",
author = "Giuseppe Frasci and Giuseppe D'Aiuto and Renato Thomas and Pasquale Comella and {Di Bonito}, Maurizio and Liliana Lapenta and Massimiliano D'Aiuto and Gerardo Botti and Paolo Vallone and {De Rosa}, Vincenzo and Roberta D'Aniello and Renato Giordano and Giuseppe Comella",
year = "2005",
month = "8",
doi = "10.1159/000086980",
language = "English",
volume = "68",
pages = "391--397",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4-6",

}

TY - JOUR

T1 - Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-paclitaxel-reffactory breast cancer patients

AU - Frasci, Giuseppe

AU - D'Aiuto, Giuseppe

AU - Thomas, Renato

AU - Comella, Pasquale

AU - Di Bonito, Maurizio

AU - Lapenta, Liliana

AU - D'Aiuto, Massimiliano

AU - Botti, Gerardo

AU - Vallone, Paolo

AU - De Rosa, Vincenzo

AU - D'Aniello, Roberta

AU - Giordano, Renato

AU - Comella, Giuseppe

PY - 2005/8

Y1 - 2005/8

N2 - Purpose: To evaluate the feasibility and activity of combination treatment with docetaxel (DTX) and irinotecan (CPT-11), given together every other week, combined with filgrastim support, in anthracycline- and paclitaxel-pretreated breast cancer (BC) patients. Patients and Methods: Advanced BC patients pretreated with anthracycline- and paclitaxel-based chemotherapy were eligible. DTX (80 mg/m2) and CPT-11 (100 mg/m2) were given biweekly with filgrastim support (300 μg/day on days 4-7). Results: Fifty patients (48 with metastatic and 2 with locally advanced cancer) were enrolled, with a total of 318 cycles being delivered. Thirty-one patients had visceral localizations. All patients had received epirubicin plus paclitaxel, with or without cisplatin, as front-line treatment for advanced disease. Overall, fatigue and diarrhea were the main chemotherapy-related toxicities in this study, being severe in 10 (20%) and 4 (8%) patients. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 18 (36%) and 6 (12%) patients, respectively. Red blood cell transfusions were required in 4 patients. A total of 32 objective responses were registered (overall response rate, ORR = 64%, 95% confidence interval = 49-77%), including 8 complete responses (16%). An additional 8 patients showed stable disease. After a median follow-up of 18 (range 4-29) months, 30 patients were still alive, and 19 were progression free; median progression-free and overall survivals were 10 and 23 months, respectively. Conclusions: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients. The very promising ORR and survival outcome observed in this subset of patients with a poor prognosis suggest that this regimen might play a major role in the management of this disease.

AB - Purpose: To evaluate the feasibility and activity of combination treatment with docetaxel (DTX) and irinotecan (CPT-11), given together every other week, combined with filgrastim support, in anthracycline- and paclitaxel-pretreated breast cancer (BC) patients. Patients and Methods: Advanced BC patients pretreated with anthracycline- and paclitaxel-based chemotherapy were eligible. DTX (80 mg/m2) and CPT-11 (100 mg/m2) were given biweekly with filgrastim support (300 μg/day on days 4-7). Results: Fifty patients (48 with metastatic and 2 with locally advanced cancer) were enrolled, with a total of 318 cycles being delivered. Thirty-one patients had visceral localizations. All patients had received epirubicin plus paclitaxel, with or without cisplatin, as front-line treatment for advanced disease. Overall, fatigue and diarrhea were the main chemotherapy-related toxicities in this study, being severe in 10 (20%) and 4 (8%) patients. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 18 (36%) and 6 (12%) patients, respectively. Red blood cell transfusions were required in 4 patients. A total of 32 objective responses were registered (overall response rate, ORR = 64%, 95% confidence interval = 49-77%), including 8 complete responses (16%). An additional 8 patients showed stable disease. After a median follow-up of 18 (range 4-29) months, 30 patients were still alive, and 19 were progression free; median progression-free and overall survivals were 10 and 23 months, respectively. Conclusions: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients. The very promising ORR and survival outcome observed in this subset of patients with a poor prognosis suggest that this regimen might play a major role in the management of this disease.

KW - Biweekly administration

KW - Breast cancer

KW - Docetaxel

KW - Irinotecan

UR - http://www.scopus.com/inward/record.url?scp=23844545209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844545209&partnerID=8YFLogxK

U2 - 10.1159/000086980

DO - 10.1159/000086980

M3 - Article

C2 - 16020968

AN - SCOPUS:23844545209

VL - 68

SP - 391

EP - 397

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4-6

ER -